ProCE Banner Activity

RELATIVITY-047: Biomarker Analysis of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma

Conference Coverage
Slideset

Exploratory biomarker analysis of patients with previously untreated advanced melanoma in RELATIVITY-047 suggests that expansion of selected immune cell populations is more prominent with nivolumab + relatlimab vs nivolumab alone and that lower pretreatment CD8+ T-cell levels in tumors may be associated with increased benefit from nivolumab + relatlimab vs nivolumab alone.

Released: October 25, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc